Veru (NASDAQ:VERU) Now Covered by Analysts at Westpark Capital

Research analysts at Westpark Capital initiated coverage on shares of Veru (NASDAQ:VERU) in a note issued to investors on Tuesday, Marketbeat.com reports. The brokerage set a “buy” rating on the stock.

A number of other brokerages have also commented on VERU. Wall Street Zen lowered Veru from a “hold” rating to a “sell” rating in a research report on Sunday, September 27th. Weiss Ratings upgraded Veru from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 2nd. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Veru has an average rating of “Moderate Buy” and an average target price of $24.50.

Veru Stock Down 0.4%

NASDAQ:VERU traded down $0.01 during mid-day trading on Tuesday, reaching $2.46. 202,376 shares of the company were exchanged, compared to its average volume of 733,805. The stock has a market cap of $41.94 million, a PE ratio of -3.57 and a beta of -1.21. Veru has a 12 month low of $2.05 and a 12 month high of $7.33. The company has a fifty day moving average of $2.54 and a 200 day moving average of $2.53.

Veru (NASDAQ:VERU) last announced its earnings results on Monday, August 10th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.02. On average, equities research analysts anticipate that Veru will post -1.07 EPS for the current fiscal year.

Institutional Trading of Veru

A number of institutional investors have recently modified their holdings of VERU. FNY Investment Advisers LLC acquired a new stake in shares of Veru in the second quarter valued at approximately $328,000. Royal Bank of Canada boosted its holdings in Veru by 69.3% during the first quarter. Royal Bank of Canada now owns 12,239 shares of the company’s stock worth $27,000 after purchasing an additional 5,008 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new position in Veru in the first quarter valued at $153,000. 47.16% of the stock is currently owned by institutional investors.

Veru Company Profile

Veru Inc is a clinical-stage biopharmaceutical company focused on developing medicines for obesity, oncology and related conditions. The company’s research programs are designed to address cancer-related muscle loss and treatment challenges, as well as the loss of lean muscle that can accompany significant weight reduction.

Veru’s lead investigational product, enobosarm, is an oral selective androgen receptor modulator being studied for its potential to preserve or increase muscle mass and improve physical function.